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Summary Immunohistochemical assays have been employed to study the expression of ER, PgR, EGFR and
Ki67 immunostaining in normal breast tissue (n = 76). The expression of ER and PgR was highly variable in
both pre and postmenopausal women and was characterised by large numbers of apparently negative cells.
This was most evident for ER-ICA staining in tissues removed from premenopausal women. PgR levels were
highest in the ducts of premenopausal women, while EGFR expression was elevated in both ducts and lobules.
Ki67 expression was observed in < 10% of all normal cells and was suppressed by the menopause in lobular
tissue.
Tamoxifen therapy (40 mg d-') did not influence the expression of PgR, EGFR or Ki67 immunostaining in
cancer associated normal tissue (n = 17). A significant increase, however, was observed in the mean percentage
ER positivity in ductal tissue. No effect of duration of tamoxifen therapy was observed on the expression of
the antigens studied.
A number of recent publications have suggested that breast
cancer might be prevented by the antihormonal treatment of
women who are deemed to be at high risk of developing the
malignancy (Fentiman, 1989; Powles et al., 1989). The con-
cept is largely based on the epidemiological observations that
an early age of natural menopause or early oophorectomy
for reasons other than breast cancer, substantially reduces
the incidence of the disease (Pike et al., 1989). Currently
tamoxifen is the most likely candidate for such a prophylactic
regime, since the antioestrogen has not only proven
effectiveness in both primary (SBCT report, 1987; Nato
report, 1990) and advanced (Patterson et al., 1981; Furr &
Jordan, 1984) breast cancer, but also shows a low incidence
of side-effects. Moreover, in primary breast cancer patients
treated with tamoxifen as an adjuvant to surgery it has now
been observed that there is a reduction in the development of
contralateral breast cancer, suggesting that the drug is indeed
preventing the development of the disease (Nato report,
1990). Unfortunately, one of the major concerns about tam-
oxifen is that little is known of its effects on normal breast
tissue. This is of particular concern since animal experiments
have demonstrated that tamoxifen can show oestrogen-like
properties (Furr & Jordan, 1984) and is capable of pro-
moting full ductal development in the rat mammary gland
(Nicholson et al., 1988). Similar actions on normal human
breast tissue would obviously negate its suitability as a pro-
phylactic agent.
On this basis we have undertaken a study to characterise
the in vivo actions of tamoxifen on normal human breast
tissue in relation to its expression of oestrogen (ER) and
progesterone (PgR) receptors and the epidermal growth fac-
tor receptor (EGFR). The specimens have also been exam-
ined for the presence of a cell cycle related protein measured
by the Ki67 antibody. Cell cycle analysis has shown that Ki67
immunostaining occurs throughout the cell cycle (G,,S,
G2 + M) but not in Go (Gerdes et al., 1984) and thus enables
an estimate of the tissue growth fraction (Gerdes et al., 1984;
Gerdes et al., 1986). In breast tumours a significant correla-
tion has been recorded between Ki67 immunostaining and the
mitotic activity of breast cancer (Gerdes et al., 1986; Bouz-
ubar et al., 1989) and with early recurrence of the disease
after mastectomy (Bouzubar et al., 1989).
Patients and methods
Normal breast tissue was obtained from the perimeter of
benign biopsies and cancer associated 'normal' tissue from
mastectomy specimens. Tamoxifen-treated, cancer associated
normal breast tissue was acquired from 17 patients attending
Mr Price-Thomas' breast clinic at Newport. Patients received
40 mg of tamoxifen daily from presentation of their disease
to mastectomy (4 days-3 weeks). Tissues were also obtained
from breast cancer patients on long-term tamoxifen therapy
who had subsequently developed a tumour in the contra-
lateral breast. The menopausal status and age of each patient
was recorded.
Assay procedures
The immunohistochemical detection of ER was carried out
using an assay kit developed by Abbott Diagnostics (Abbott
Laboratories, North Chicago) as previously documented
(Walker et al., 1988). Measurement of PgR was carried out
using. an antibody (KD68) to the progesterone receptor
(mouse anti human) supplied by Professor Greene (Ben May
Laboratories, Chicago, USA). This antibody was substituted
for the primary ER antibody in the ER-ICA.
Ki67 immunostaining was performed using methods pre-
viously described (Bouzubar et al., 1989). The immunohis-
tochemical detection of EGFR was undertaken using a
previously unpublished procedure. Briefly, cryostat sections
(5 Lm) were mounted on slides coated with a tissue adhesive
and air dried for at least 2 h and stored at - 70'C prior to
assay. Sections were fixed in acetone/chloroform (1:1) at 4'C
for 10min then washed in Tris buffered saline (10 mM Tris,
pH 7.4; TBS) before incubation with a normal goat serum
(diluted 1:10 with TBS) for 10 min. Excess serum was
removed and the slides were incubated for a further 60 min
with the primary antibody (1 Lg ml final concentration,
Amersham, UK) in 10% normal goat serum and 5% normal
human serum in TBS). The slides were washed three times in
TBS and reincubated for 30 min with rabbit anti-mouse
peroxidase conjugate (diluted 1:50 in 10% normal goat
serum and 5% normal human serum in TBS) followed by 2
washes in TBS. Sections were immersed for 6 min in a
chromogen substrate bath containing DAB (150 mg) and
imidazole (150 mg) in 300 ml TBS, to which had been added
99 il of 30% (w/v) hydrogen peroxide. The reaction was
stopped by washing the sections for 1 min in distilled water
followed by a further 1 min exposure to 0.5% CuSO4 in
0.85% NaOH which enhances the end product colouration.
The sections were counterstained with methyl green (1%
aqueous) for 6 min. The slides were then rinsed in tap water
for 5 min, dehydrated in serially graded alcohols, cleared in
Correspondence: R.I. Nicholson, Tenovus Institute for Cancer Re-
search, University of Wales College of Medicine, Heath Park, Cardiff
CF4 4XX, UK.
Received 26 March 1991; and in revised form 14 May 1991.
Br. J. Cancer (I991), 64, 764 768 '." Macmillan Press Ltd., 1991EFFECTS OF TAMOXIFEN ON NORMAL BREAST TISSUE 765
xylene and mounted under coverslips in dibutylpthalate xy-
lene solution. Control slides in which the primary antibody
had been replaced with an equivalent concentration of mouse
anti-sheep erythrocytes were included in each assay, enabling
assessment of non-specific binding. A highly EGFR positive
tumour was also incorporated into each assay as a positive
control.
Specimen evaluation
All specimen evaluation was performed on an Olympus
microscope (BH-2) using an occular magnification of x 40.
Control slides were checked for non-specific binding before
assessing the percentage of cells stained by the primary
antibodies. Quantitative assessments were made for each
antigen of the number of positive and negative stained cells
in 20 samples. For each tissue a total of 10 fields were
counted and a mean percentage staining figure was cal-
culated. After a lapse of 2 weeks the same samples and fields
were re-evaluated by two personnel using a dual viewing
attachment to the Olympus microscope estimating the num-
bers of positive and negative cells. Comparison of the results
obtained using both methods of assessment demonstrated
excellent agreement (r=0.82, P<0.01). The latter method
was therefore used throughout the study.
Results
Untreated breast tissue
In normal breast tissue from control patients, the immuno-
histochemical localisation of ER using the antihuman ER rat
monoclonal antibody H222 showed specific binding in the
nuclei of epithelial cells with no binding being observed in
the cytoplasm or stromal components. Considerable hetero-
geneity of ER expression was, however, evident in both
ductal (Plate la) and lobular (Plate lb) structures. Examina-
tion of the distribution of ER positivity in lobules indicated a
trend for an increase in the proportion of ER positive cells in
postmenopausal women (Figure la; P = 0.02). Values for ER
positivity in ductal tissue were lower than those obtained in
lobular specimens and were similar in both pre- and post-
menopausal women (Figure lb).
The distribution of the progesterone receptor in normal
breast tissue was similar to that observed for ER with the
majority of parenchymal structures showing variable num-
bers of positive cells (Plate lc,d). Unlike ER, however, PgR
expression was highest in premenopausal women with this
achieving significance (P = 0.04) in the ductal components
(Figure lc,d). Examination of EGFR in normal tissue
showed a consistently high expression of cell membrane
staining in both ducts and lobules (Plate le,f). The staining
was most evident towards the basement membrane, with
luminal epithelial cells occasionally being recorded as nega-
tive. No obvious differences were observed in EGFR levels
between pre and postmenopausal women and between ducts
and lobules (not illustrated). Due to the high proportion of
positive EGFR cells and their distribution in normal struc-
tures it was not possible to quantify EGFR measurements.
Ki67 binding in all normal breast tissues examined was
much lower than that recorded with the other antibodies
with characteristically < 10% cells immunostaining (Plate
lg,h, Figure le,f). Indeed in 25% of the samples no Ki67
immunostaining was recorded. Highest levels of Ki67 positiv-
ity were observed in the lobules removed from premeno-
pausal women (P = 0.02).
Tamoxifen treated normal breast tissue
Examination of the above parameters in 15 postmenopausal
and two premenopausal tamoxifen treated women showed
that the antioestrogen did not influence ER expression in the
lobular component of normal breast tissue in comparison to
postmenopausal controls (median values 30 and 20 respec-
tively). It did, however, result in a significant increase in the
percentage of ER positive ductal breast cells with more
homogenous staining patterns being established (median val-
ues 30, and five respectively for tamoxifen treated and con-
trol postmenopausal patients, Figure 2b). Treatment with the
antioestrogen did not influence the immunostaining patterns
for PgR, Ki67 (Figure 2c-f) and EGFR (not illustrated). The
mean Ki67 positivity in tissues from all tamoxifen treated
patients remained below 5%. No obvious influence of the
duration of tamoxifen treatment was apparent on the expres-
sion of ER, PgR and Ki67 (Figure 3).
Discussion
The antioestrogen tamoxifen has been suggested as a suitable
prophylactic agent for the prevention of breast cancer in
women who are deemed to be at high risk of developing the
disease. This is in spite of very little information being
available concerning the actions of the antioestrogen on the
parenchymal structures of the normal breast. In our current
study we have been able to establish using a number of
immunohistochemical markers of hormone and growth factor
receptors and a cell proliferation marker, that although
tamoxifen may upregulate ER expression in ductal structures
removed from postmenopausal treated patients, it shows no
stimulatory activity on either PgR levels, a well known oes-
trogen regulated protein (Katzenellenbogen et al., 1987;
Welshons et al., 1987) or the important parameter of cell
proliferation (Figure 2). This is despite each of these end
points showing a degree of hormonal regulation in non-
treated patients, with their levels being modified by meno-
pausal status (Figure 1).
Since Ki67 immunostaining occurs at low frequency in the
breast tissue of postmenopausal women (<5% cell staining)
we envisaged that any stimulatory activity of tamoxifen on
cell proliferation should have been readily detected. The
absence of any increases in the proportion of Ki67 positive
cells in any of the samples removed from women after both
short (2 days to 1 month) and long (>2 months) term
tamoxifen treatment (Figure 3) suggests no adverse actions of
the drug on normal breast tissue. Although our current study
was largely performed on postmenopausal women, two sam-
ples removed from tamoxifen-treated premenopausal women
also showed no evidence of elevated rates of cell prolifera-
tion. The ER and PgR values recorded in these specimens,
however, were above the median values for the group in both
ducts and lobules.
The data recorded above is in contrast to the oestrogen-
like activity of tamoxifen on the human pituitary gland,
uterus and liver of postmenopausal women, where the drug
reduces elevated gonadotrophin levels (Furr & Jordan, 1984),
increases the karyopyknotic index of the uterus (Ferrazzi et
al., 1977) and increases the serum concentrations of several
oestrogen-regulated liver proteins (Sakai et al., 1978; Boc-
cardo et al., 1981; Fex et al., 1981). These results reflect the
complex pharmacology of tamoxifen which is species, tissue
and cell type specific (Furr & Jordan, 1984) and whose
properties can range from a full oestrogen with no antagonis-
tic properties towards oestradiol, to a full antagonist with no
oestrogenicity. Indeed, we have previously ascribed the for-
mer property to tamoxifen with regards to its action on the
rat mammary gland where it is a full agonist on ductal
development and stimulates a large proliferative response in
the terminal end buds, the main growth regions of the gland
(Nicholson et al., 1988). These studies were, however, carried
out on pubertal animals during the active growth phase of
mammary gland development. In mature cycling animals
tamoxifen acts as an antioestrogen causing atrophy of
lobular structures (Gotz et al., 1984). In this light it may be
significant that tamoxifen treatment of postmenopausal
women resulted in some upregulation of the proportion of
ductal epithelial cells expressing ER. Since, a similar
phenomenon occurs in the transition between pre- and post-
menopausal women, in both the normal (Figure 1) and766 K.J. WALKER et al.
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Plate 1 Normal breast cells in ductal (a,c,e,g) and lobular (b,d,f,h) structures immunostained for ER (a,b), PgR (c,d), EGFR (e,f)
and Ki67 (g,h).
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Figure 1 Influence of the menopause on immunostaining pat-
terns in breast tissue. The data are presented as the percentage of
normal breast cells in lobular structures (a,c,e) and ducts (b,d,f)
that are ER (a,b), PgR (b,c) and Ki67 (e,f) positive and are
subdivided according to the menopausal status of the patient.
Mean values for the groups are shown by the dotted lines. The P
values calculated for differences between pre- and post-meno-
pausal groups are a, P = 0.02, b, P = 0.53, c, P = 0.06, d,
P=0.04, e, P=0.02, f, P=0.43.
cancerous breast (Walker et al., 1988), it is possible that the
further increase observed in tamoxifen treated women may
reflect a more efficient reduction in the availability of oest-
rogens to the tissue mediated by the antioestrogenic actions
of the drug.
High levels of EGFR expression were evident in all normal
breast tissue from both treated and untreated patients. Stain-
ing was, however, more frequently associated with the basal
component, with luminal cells sometimes appearing EGFR
negative. In view of the high level of EGFR positivity no
correspondence was observed between its expression and
immunostaining for ER, PgR and Ki67. These data are in
contrast to the inverse relationship between ER and EGFR
expression observed in breast tumours (Sainsbury et al.,
1985), where EGFR immunostaining is associated with high
grades of tumour malignancy (Lewis et al., 1990). Moreover,
in breast cancer specimens Ki67 immunostaining also cor-
relates with EGFR expression (McClelland & Nicholson, in
preparation) and poor prognosis (Sainsbury et al., 1987).
These differences may result from the low availability of the
ligands for the EGFR in normal tissues (Elder et al., 1975;
Kaselberg et al., 1985; Poulsen et al., 1986) and the presence
of readily detectable amounts of TGF-a, the tumour homo-
logue of EGF in the majority of breast cancers (Macias et
al., 1989).
In conclusion, the data presented do not show any adverse
effects of tamoxifen on normal breast tissue. Most impor-
tantly treatment with the antioestrogen does not appear to
stimulate cell proliferation even on long-term therapy. These
data are therefore reassuring when considering the use of
tamoxifen in ostensibly normal women who are deemed to be
at high-risk of developing breast cancer.
Figure 2 Influence of tamoxifen on immunostained patterns in
breast tissue. The data are presented as the percentage of normal
breast cells in lobular structures (a,c,e) and ducts (b,d,f) that are
ER (a,b), PgR (b,c) and Ki67 (e,f) positive in tamoxifen treated
(40 mg d-') and control patients. The majority of women receiv-
ing tamoxifen were postmenopausal (@) and are compared with
control postmenopausal patients. The results obtained from two
premenopausal women treated with the antioestrogen are illus-
trated by the symbol (A). Mean values for the groups are shown
by the dotted lines. The P values calculated for differences
between control and tamoxifen treated groups are a, P = 0.23, b,
P=0.005, c, P=0.80, d, P=0.17, e, P=0.28 and f, P=0.47.
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Figure 3 Influence of the duration of tamoxifen therapy on
immunostaining patterns in breast tissue. The data are presented
as the percentage of normal cells in ducts (@) and lobules (A)
that are ER, PgR and Ki67 positive in tamoxifen treated women
as a function of the duration of therapy. The results obtained
from premenopausal are shown by the 0 symbol.
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